Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Meng Li; Hong Zhao; Xiaosong Zhang; Laura D. Wood; Robert A. Anders; Michael A. Choti; Timothy M. Pawlik; Hubert D. Daniel; Rajesh Kannangai; G. Johan A. Offerhaus; Victor E. Velculescu; Linfang Wang; Shibin Zhou; Bert Vogelstein; Ralph H. Hruban; Nick Papadopoulos; Jianqiang Cai; Michael S. Torbenson; Kenneth W. Kinzler

doi:10.1038/ng.903

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Meng Li, Hong Zhao, Xiaosong Zhang, Laura D. Wood, Robert A. Anders, Michael A. Choti, Timothy M. Pawlik, Hubert D. Daniel, Rajesh Kannangai, G. Johan A. Offerhaus, Victor E. Velculescu, Linfang Wang, Shibin Zhou, Bert Vogelstein, Ralph H. Hruban, Nick Papadopoulos, Jianqiang Cai, Michael S. Torbenson, Kenneth W. Kinzler

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

290 Scopus citations

Abstract

Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

Original language	English (US)
Pages (from-to)	828-829
Number of pages	2
Journal	Nature Genetics
Volume	43
Issue number	9
DOIs	https://doi.org/10.1038/ng.903
State	Published - Sep 2011

ASJC Scopus subject areas

Genetics

Access to Document

10.1038/ng.903

Cite this

Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D., Kannangai, R., Offerhaus, G. J. A., Velculescu, V. E., Wang, L., Zhou, S., Vogelstein, B., Hruban, R. H., Papadopoulos, N., Cai, J., Torbenson, M. S., & Kinzler, K. W. (2011). Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature Genetics, 43(9), 828-829. https://doi.org/10.1038/ng.903

Li, M, Zhao, H, Zhang, X, Wood, LD, Anders, RA, Choti, MA, Pawlik, TM, Daniel, HD, Kannangai, R, Offerhaus, GJA, Velculescu, VE, Wang, L, Zhou, S, Vogelstein, B, Hruban, RH, Papadopoulos, N, Cai, J, Torbenson, MS & Kinzler, KW 2011, 'Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma', Nature Genetics, vol. 43, no. 9, pp. 828-829. https://doi.org/10.1038/ng.903

@article{45e85357d7b147d0ae5c51b57430e37e,

title = "Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma",

abstract = "Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.",

author = "Meng Li and Hong Zhao and Xiaosong Zhang and Wood, {Laura D.} and Anders, {Robert A.} and Choti, {Michael A.} and Pawlik, {Timothy M.} and Daniel, {Hubert D.} and Rajesh Kannangai and Offerhaus, {G. Johan A.} and Velculescu, {Victor E.} and Linfang Wang and Shibin Zhou and Bert Vogelstein and Hruban, {Ralph H.} and Nick Papadopoulos and Jianqiang Cai and Torbenson, {Michael S.} and Kinzler, {Kenneth W.}",

note = "Funding Information: We thank N. Silliman, J. Ptak, L. Dobbyn, J. Schaeffer, M. Whalen, Z. Khan, J. Ma, Z. Wang and R. Mi for expert technical assistance. This work was supported by The Virginia and D.K. Ludwig Fund for Cancer Research and US National Institutes of Health grants CA43460, CA57345, CA62924, CA121113, DK078686, DK080736, DK081417, AACR Stand Up to Cancer Dream Team Translational Cancer Research Grant and National Science and Technology Major Project Grant 2008ZX10002-025.",

year = "2011",

month = sep,

doi = "10.1038/ng.903",

language = "English (US)",

volume = "43",

pages = "828--829",

journal = "Nature Genetics",

issn = "1061-4036",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

AU - Li, Meng

AU - Zhao, Hong

AU - Zhang, Xiaosong

AU - Wood, Laura D.

AU - Anders, Robert A.

AU - Choti, Michael A.

AU - Pawlik, Timothy M.

AU - Daniel, Hubert D.

AU - Kannangai, Rajesh

AU - Offerhaus, G. Johan A.

AU - Velculescu, Victor E.

AU - Wang, Linfang

AU - Zhou, Shibin

AU - Vogelstein, Bert

AU - Hruban, Ralph H.

AU - Papadopoulos, Nick

AU - Cai, Jianqiang

AU - Torbenson, Michael S.

AU - Kinzler, Kenneth W.

N1 - Funding Information: We thank N. Silliman, J. Ptak, L. Dobbyn, J. Schaeffer, M. Whalen, Z. Khan, J. Ma, Z. Wang and R. Mi for expert technical assistance. This work was supported by The Virginia and D.K. Ludwig Fund for Cancer Research and US National Institutes of Health grants CA43460, CA57345, CA62924, CA121113, DK078686, DK080736, DK081417, AACR Stand Up to Cancer Dream Team Translational Cancer Research Grant and National Science and Technology Major Project Grant 2008ZX10002-025.

PY - 2011/9

Y1 - 2011/9

N2 - Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

AB - Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

UR - http://www.scopus.com/inward/record.url?scp=80052271807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052271807&partnerID=8YFLogxK

U2 - 10.1038/ng.903

DO - 10.1038/ng.903

M3 - Article

C2 - 21822264

AN - SCOPUS:80052271807

SN - 1061-4036

VL - 43

SP - 828

EP - 829

JO - Nature Genetics

JF - Nature Genetics

IS - 9

ER -

Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this